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 The interplay between cardiomyocytes and
cardiac ﬁbroblasts is increasingly being
recognized as important in cardiac disease.
 Fetal and adult cardiac ﬁbroblasts
inﬂuence their neighboring
cardiomyocytes in different ways. A
genome-wide comparison of the 2 reveals
that they share >80% of gene transcripts.
 Motif analysis of empirical regulatory
elements located next to differentially
expressed genes led to identiﬁcation of key
differential regulators of ﬁbroblast identity.
 STAT1 and PLAGL1 were identiﬁed and
validated as key transcription factors to
maintain the adult cardiac ﬁbroblast
phenotype. Loss of either factor led to a
signiﬁcant change in phenotype, including
smaller cell size, apoptosis, reduced
turnover, and down-regulated collagen
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AB BAND ACRONYM S
aHCF = adult human cardiac
ﬁbroblast
ATAC = assay for transposase
accessible chromatin
ATAC-seq = assay for
transposase accessible
chromatin–sequencing
CF = cardiac ﬁbroblast
ChIP-seq = chromatin
immunoprecipitation–
sequencingCardiovascular disease remains the number one global cause of death and presents as multiple phenotypes in
which the interplay between cardiomyocytes and cardiac ﬁbroblasts (CFs) has become increasingly highlighted.
Fetal and adult CFs inﬂuence neighboring cardiomyocytes in different ways. Thus far, a detailed comparison
between the two is lacking. Using a genome-wide approach, we identiﬁed and validated 2 crucial players for
maintaining the adult primary human CF phenotype. Knockdown of these factors induced signiﬁcant phenotypical
changes, including senescence and reduced collagen gene expression. These may now represent novel thera-
peutic targets against deleterious functions of CFs in adult cardiovascular disease. (J Am Coll Cardiol Basic Trans
Science 2016;1:590–602) © 2016 The Authors. Published by Elsevier on behalf of the American College of Car-
diology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
cardiomyocyteCM =ECM = extracellular matrix
EMT = epithelial-to-
mesenchymal transformation
FGF = ﬁbroblast growth factor
fHCF = fetal human cardiac
ﬁbroblast
HCF = human cardiac ﬁbroblast
IL = interleukin







transcription factorA lthough cardiomyocytes (CMs) occupymost ofthe tissue volume and provide the mechanicalforce delivered by the heart, they are largely
outnumbered by nonmyocyte cells (30% vs. 70%),
part of which are cardiac ﬁbroblasts (CFs) (1,2). Cross-
sectional confocal microscopy of ventricular tissue re-
veals that each CM is in the direct vicinity of at least 1
CF (3), reﬂecting a signiﬁcant role for CFs in the heart;
that is, to create and hold a supportive environment
for CMs, such as by regulation of the extracellular ma-
trix (ECM). More than simply a “scaffold cell,” CFs are
understood to communicate with CMs in 3 different
ways. The ﬁrst method is through direct cell-to-cell
contact, in which the formation of adherens junctions
(cadherins) and gap junctions (connexins) play a
crucial role (4). The second method is by paracrine or
autocrine secretion of growth factors such as ﬁbro-
blast growth factor (FGF)-2/basic FGF and transform-
ing growth factor–b or important cytokines such as
interleukin (IL)-1b and the IL-6 family, including
leukemia inhibitory factor and cardiotrophin-1 (5). In
the third method, cells indirectly relay signals via
the ECM by modulating its composition and quantity
by secretion or degradation of the ECM building
blocks (4,6).SEE PAGE 603Common features of ﬁbroblasts are the lack of a
basement membrane, profound granular material in
the cytoplasm scattered along a large Golgi apparatus,
and a substantial rough endoplasmic reticulum (7). A
unique marker for ﬁbroblasts or CFs is still lacking,
although both fetal and adult CF express periostin,
discoidin domain receptor 2, and vimentin (8). Another
feature of CFs is their ability to transform into an active
state; the myoﬁbroblast. Myoﬁbroblasts express
smoothmuscle cell markers (e.g., smoothmuscle actin
[SMA]) and may contract. They have also been impli-
cated in wound contraction, ﬁbrosis, and scar healingand are a source of cytokines and
growth factors, such as IL-6 and transforming
growth factor–b (9).
Fibroblasts are abundant throughout all
tissues in the body, and the population is
heterogeneous, with diverse appearances and
functions depending on where the cells reside
(10). Apart from the expression of common
core ﬁbroblast genes, a speciﬁc gene ex-
pression proﬁle involving the cardiogenic
transcriptional network has been described
uniquely for CFs (11). Furthermore, regional
differences exist in which CFs from the atrium
and the ventricle express different cardio-
genic transcription factors (TFs) (11,12). Important
differences have also been found between rat CFs from
the embryonic heart compared with the adult heart,
with a differential response in insulin-like growth
factor–induced collagen production (13). The inﬂuence
of CFs on co-cultured CMs also varies depending on
age. Embryonic CFs increase proliferation of CMs,
whereas adult CFs induce hypertrophy (6). Notably,
this ﬁnding is consistent with the growth of a fetal or
neonatal heart, which depends on the proliferation of
CMs, whereas the adult heart responds to stress by
hypertrophy. The diversity of the CF population is also
underlined by the ﬁnding that CF may be derived from
at least 3 sources: from the proepicardium, from
endocardial- or epicardial-to-mesenchymal trans-
formation (EMT), and from bone marrow (14–16).
Despite increasing attention to the potential role
that CF may play in novel disease therapeutics (17), a
detailed genome-wide characterization of the genetic
and epigenetic proﬁles of CF has yet to be performed.
In the present study, we conducted next-generation
sequencing experiments with primary ventricular
fetal human cardiac ﬁbroblasts (fHCFs) and adult
human cardiac ﬁbroblasts (aHCFs) to carefully map
their respective transcriptomic and epigenomic
TF =
TABLE 1 Clinical Characteristics of the fHCFs and aHCFs Used in This Study
Company Catalog No./Lot No. Ethnicity Sex Age Clinical Proﬁle Site of Isolation
fHCF
Cell Applications, Inc. 306-05f/1916 Black Female 16 weeks gestation Normal human fetal heart Ventricle
Cell Applications, Inc. 306-05f/2112 Unknown Female 21 weeks gestation Normal human fetal heart Ventricle
aHCF
PromoCell C-12375/3042901.1 White Male 54 yrs Histologically normal tissue Ventricle
PromoCell C-12375/397Z030.3 White Female 30 yrs Histologically normal tissue Ventricle
PromoCell C-12375/1051601.5 White Male 48 yrs Histologically normal tissue Ventricle
Isolation methods are proprietary.
aHCFs ¼ adult human cardiac ﬁbroblasts; fHCFs ¼ fetal human cardiac ﬁbroblasts.
FIGURE 1 Cellular
(A) Fetal human card
2-phenylindole (DAP
t test. (C) Flow cyto
endothelial cell (aHC
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592proﬁles, with the aim of unraveling key players
responsible for maintaining the CF phenotype.
METHODS
Detailed Methods are available in the Supplemental
Appendix. aHCFs were purchased from PromoCell
(Heidelberg, Germany; catalog no. C-12375, lot no.
3042901.1, lot no. 397Z030.3 and lot no. 1051601.5),Characterization of fHCFs and aHCFs
iac ﬁbroblasts (fHCFs) (top) and adult human cardiac ﬁbroblasts (aHCFs) (b
I) (blue). (B) Quantiﬁcation to show that fHCFs are smaller in size and prolif
metry analysis show that aHCFs and fHCFs express THY-1 and PDGFRA but a
AEC) or THP-1 (a human monocytic cell line) were used as control cell typesand fHCFs were purchased from Cell Applications,
Inc. (San Diego, California; catalog no. 306-05g, lot
no. 1916, and lot no. 2112). The ﬁbroblasts were of
ventricular origin, and all donors were free of cardiac
disease. Proﬁling experiments were performed with
human cardiac ﬁbroblasts (HCFs) between passages
3 and 4. Cellular, molecular, and next-generation
sequencing experiments were performed as
described in the Supplemental Appendix. Primerottom) stained for vimentin (red), Ki67 (green), and 40,6-diamidino-
erate more than aHCFs. Values are mean  SD; *p < 0.05, Student
re negative for PECAM1 and CD45. Adult human coronary artery
.
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593sequences for reverse transcription–quantitative
polymerase chain reaction (RT-qPCR) are listed in
Supplemental Table 1.
STATISTICAL ANALYSIS. Ribonucleic acid–sequencing
(RNA-seq) data were aligned to the Hg19 reference
genome by using TopHat version 2.0.11 (Center for
Computational Biology at Johns Hopkins University,
Baltimore, Maryland). The transcriptome was assem-
bled by using Cufﬂinks version 2.2.1 (Laboratory for
Mathematical and Computational Biology at UC
Berkeley; Computational Genomics at the Institute
of Genetic Medicine at Johns Hopkins University, Bal-
timore, Maryland; Caltech, Pasadena), and differential
expression of genes was analyzed in GENCODE
gene annotation version 16 (Wellcome Trust
Sanger Institute, Cambridge). Differentially expressed
genes were selected on the basis of q value (false dis-
covery rate–corrected p value) and log2fold-change
produced by Cuffdiff. Chromatin immunoprecipita-
tion–sequencing (ChIP-seq) and assay for transposase
accessible chromatin–sequencing (ATAC-seq) peaks
were called by using DFilter (18). Filter types for
H3K4me3 and ATAC were zero mean, whereas
H3K27me3 was interrogated by using a nonzero mean.
Filter width settings for H3K4me3, H3K27me3, and
ATACwere as follows: 8 to 10 kb, -ks¼ 100, -bs¼ 100; 1.5
to 3 kb, -ks ¼ 25, -bs ¼ 100; and 4 to 5 kb, -ks ¼ 50, -bs ¼
100, respectively. Expected peak cutoff p values for
H3K4me3, H3K27me3, and ATACwere set at 1E-6, 1E-3,
and 1E-2 according to Dﬁlter recommendations. Peak
annotation was performed by using ChIPpeakAnno
(19). Known motifs and de novo motifs from ChIP-seq
data were obtained by HOMER Motif Analysis (20).
Two-tailed unpaired Student t tests were used to
assess signiﬁcance in the RT-qPCR and immuno-
staining analysis. Results are presented as mean  SD,
and statistical signiﬁcance is denoted in the graphics
as p #0.05.
RESULTS
CELLULAR CHARACTERIZATION OF CFs. fHCFs
and aHCFs were characterized with the use of
immunocytochemistry and ﬂow cytometry. Clinical
characteristics of the cell isolates are listed in Table 1.
Immunocytochemical labeling was performed for
vimentin and Ki67 (proliferation marker). Represen-
tative images are shown in Figure 1A and are quanti-
ﬁed in Figure 1B. Image analysis of more than 2,000
cells in independent cultures showed that fHCFs were
consistently smaller than aHCFs (802  46 mm2 vs.
2,127  131 mm2) and proliferated faster. Ki67-positive
cells for fHCFs and aHCFs were 63% and 52%,respectively, representing higher proliferation in the
former. A higher turnover of fHCFs compared with
aHCFs was also substantiated by a shorter doubling
time of 34.6 h and 68.9 h, respectively (data provided
by the supplier). More than 98% of cells were a-SMA
negative (Supplemental Figure 1), ensuring that the
majority of the study CFs were not activated to
myoﬁbroblasts by stress conditions of cell culture.
Flow cytometry results proved that both fHCFs and
aHCFs expressed THY-1 and PDGFRA. Moreover,
FACS also allowed us to exclude the possibility that
the study cells were contaminated with other cells of
endothelial (PECAM1 negative) or hematopoetic
(CD45 negative) origin (Figure 1C).
TRANSCRIPTOMIC CHARACTERISTICS. RNA-seq was
performed for both fHCFs and aHCFs (n ¼ 3)
(Supplemental Figure 2A). We used the stringent cut-
off of fragments per kilobase of exon per million
fragments mapped >1 to call genes expressed in both
aHCFs and fHCFs. A total of 13,400 genes were
expressed in both, with 1,639 and 1,354 being exclu-
sively expressed in fHCFs and aHCFs, respectively
(Figure 2A). Thus, aHCF and fHCF transcriptomes
exhibited marked similarities, raising the important
question of whether speciﬁc transcriptomic differ-
ences might deﬁne their unique phenotypic charac-
teristics. Figure 2B shows a heat map of exclusively
expressed genes, which expectedly segregate the 2
sets of fHCF and aHCF samples. Supplemental
Appendix 2 lists all genes expressed in the 2 sets of
HCFs and their corresponding expression values.
Correlation comparisons between sample replicates
in Figure 2C corroborate the distinction between
aHCFs and fHCFs (correlation of fHCF replicates in
blue is w0.98, and the same for aHCF replicates in
red, contrasting against lower correlations compared
across fHCFs and aHCFs in purple).
We next sought to interpret gene expression sig-
natures that distinguished between fHCFs and aHCFs
and started by performing Ingenuity Pathway
Analysis (IPA, Qiagen GmbH, Hilden, Germany).
Supplemental Table 2 displays the highest signiﬁcant
genes with a log fold-change aHCF > fHCF of >4 or
<–4. Using the list of differentially expressed genes, a
selection was made according to manual curation for
relevance on the basis of results of a thorough liter-
ature search. Selected genes were validated by using
RT-qPCR (Supplemental Figure 2B) and biologically
replicated in 3 additional independent HCF cell iso-
lates (2 for adult and 1 for fetal) (Supplemental
Figure 2C). Mean gene expression in aHCFs versus
fHCFs by using RT-qPCR supported the RNA-seq data
for all 24 genes tested.
FIGURE 2 Similarities and Differences Between the Transcriptomes of fHCFs and aHCFs
Continued on the next page
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FIGURE 3 ATAC-Seq and Histone ChIP-Seq of Both Cell Types Accurately Map Out Epigenomic Proﬁles That Corroborate the Corresponding Transcriptomes
(A) Overlap of loci for assay in transposase accessible chromatin–sequencing (ATAC-seq) (open chromatin) and chromatin immunoprecipitation–sequencing (ChIP-seq)
for H3K4me3 (active promoters) and H3K27me3 (repressed domains) in Venn diagrams. (B) Distribution of ATAC-seq and histone ChIP-seq peaks around transcription
start sites (TSS) of genes. ATAC (red), H3K4me3 (green), and H3K27me3 (blue) peaks are plotted to show their enrichment around TSS. The x-axis shows the distance in
kilobase centered on gene TSS; the y-axis depicts the enrichment of peaks. (C) Genome-wide density plots showing that ATAC-seq and H3K4me3 enrichment at TSS
correspond well to genes that are highly expressed, whereas H3K27me3 are more spread out across TSS of genes that are lowly expressed. Blue indicates density signals
for ATAC, H3K4me3, and H3K27me3 enrichment at each TSS gene locus 5 kb represented in each row. Purple indicates expression level in fragments per kilobase of
exon per million fragments mapped (FPKM), of the corresponding gene in each row. RNA-seq ¼ ribonucleic acid–sequencing.
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595The top 1,000 differentially expressed genes on
the basis of their log-fold difference were fed into
IPA to perform a comparison analysis. Canonical
pathway analysis of the lists revealed that genes
from ephrin receptor signaling, IL-8 signaling, and
Notch signaling were statistically enriched in the
fetal transcriptome, whereas IL-6 signaling, among
others, was enriched in the adult transcriptome.
Figure 2D provides the IPA summary for the top
canonical pathways and the physiological system
development and functions with their respectiveFIGURE 2 Continued
(A) A Venn diagram of genes expressed in aHCFs (orange) and fHCFs (blu
between replicates of independent fHCF and aHCF samples (fHCF replic
hits of both canonical pathways analysis and physiological system deve
by using Ingenuity Pathway Analysis (Qiagen GmbH, Hilden, Germany).
aHCFs, as well as genes exclusively expressed in each. fpkm ¼ fragmen
shown in Figure 1.p values. Both transcriptomes contained genes
involved in tissue development and cardiovascular
system development, potentially representing a
common phenotype for CFs regardless of adult or
fetal origins. In contrast, immune cell trafﬁcking was
an aHCF hallmark, and embryonic development
was an fHCF hallmark. Gene ontology analysis for
molecular functions, cellular processes, and biolog-
ical processes was also consistent with the IPA
pathways, and results are listed in Supplemental
Figure 3. All together, we curated a list of genes toe). (B) Heat map of genes exclusively expressed segregating fHCFs from aHCFs. (C) Correlation
ates in blue box, aHCF in red box, and fHCF–aHCF cross-comparison in purple box). (D) Top 5
lopment and function for transcriptomes of both aHCFs and fHCFs, with p values determined
(E) Heat map showing representative genes that are commonly expressed in both fHCFs and
ts per kilobase of exon per million fragments mapped; IL ¼ interleukin; other abbreviations as
TABLE 2 Summary of 10 Representative Genes, Their Expression Level









VIM Fetal þþþ þ þþþ –
Adult þþþ þþþ þþþ –
POSTN Fetal þþþ þ/– þþþ –
Adult þþ þ/– þ/– –
HBEGF Fetal þ þþ þþþ –
Adult þ/– þ þ –
IL6 Fetal þþ þ/– þþþ –
Adult þþþ þþ þþ –
FGF7 Fetal – – – –
Adult þþ – þþ –
ITGA8 Fetal – þ/– þ þþ
Adult þþ þþ þþþ –
ELN Fetal – þ/– – þ
Adult þ þ þþþ –
CRYAB Fetal – þ/– – þ
Adult þþ þ þþþ –
IL1B Fetal þþ þ þþþ –
Adult þ/– þþ þ/– –
VCAM1 Fetal þ þ/– þþþ –
Adult – þ/– þ –
The intensity of the signal is ranked from – (no signal) to þþþ (strong signal) according to the
criteria grouped as noted here. Ribonucleic acid–sequencing (RNA-seq): þþþ, >800.00; þþ,
100.00 to 799.99; þ, 10.00 to 99.99; þ/–, 2.00 to 9.99; and –, <2.00. Assay for transposase
accessible chromatin–sequencing (ATAC-seq)/histone chromatin immunoprecipitation–sequencing
(ChIP-seq): þþþ, >15; þþ, 10 to 15; þ, 5 to 10; þ/–, 2 to 5; and –, <2.
HCF ¼ human cardiac ﬁbroblast.
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596display those that were: 1) highly expressed in both
aHCFs and fHCFs; 2) highly expressed in fHCFs but
not in aHCFs; or 3) highly expressed in aHCFs but
not in fHCFs (Figure 2E). Examples of genes differ-
entially overexpressed in aHCFs include FGF7,
ITGA8, CRYAB, ELN, and TNFRSF11B, whereas genes
overexpressed in fHCFs include IL1B, POSTN,
HBEGF, and VCAM.
EPIGENETIC CHARACTERISTICS: CHROMATIN
ACCESSIBILITY AND HISTONE MARKS. ATAC-seq
was performed to assess chromatin accessibility.
Quality control of ATAC-seq libraries veriﬁed the
expected nucleosomal pattern both before and after
sequencing (Supplemental Figures 4A and 4B). A total
of 63,829 peaks were identiﬁed for fHCFs and 77,614
for aHCFs by using criteria as detailed in the Methods
section. The HCF epigenome was further character-
ized by mapping active and repressed gene regulatory
domains using chromatin immunoprecipitation fol-
lowed by next-generation sequencing (ChIP-seq) for
histone marks of H3K4me3 (representing active pro-
moters) and H3K27me3 (representing repressed
genomic domains). A total of 22,662 and 25,449 peaks
were detected for H3K4me3 in fHCFs and aHCFs,respectively, whereas 8,446 and 6,330 were detected
for H3K27me3. By integrating the ATAC-seq loci with
the 2 sets of histone ChIP-seq loci, we conﬁrmed that
ATAC-seq mainly overlaid active promoters
(H3K4me3) but not repressed domains (H3K27me3)
(Figure 3A). Analysis for the loci of ATAC, H3K4me3,
and H3K27me3 revealed that all 3 signals were
enriched around transcription start sites of genes
(Figure 3B). We further integrated transcriptome
(RNA-seq), ATAC-seq, and histone ChIP-seq datasets
and conﬁrmed that loci of H3K4me3 and ATAC-seq
corresponded consistently with each other, repre-
senting loci of open chromatin and active promoters.
In contrast, these loci differed from H3K27me3 peaks,
representing repressed domains. Similarly, highly
expressed genes corresponded with ATAC-seq and
H3K4me3 loci but not with H3K27me3 (Figure 3C). As
examples, the epigenomic and transcriptomic proﬁles
of 2 genes, ELN (highly expressed in aHCFs) and
POSTN (highly expressed in fHCFs), are shown in
Supplemental Figures 5A and 5B. Table 2 provides the
expression proﬁles of some expressed genes along
with their epigenetic proﬁle.
IDENTIFICATION OF TFs FROM MOTIF ANALYSIS.
Having conﬁrmed the consistency and validity of our
genome-wide transcriptomic and epigenomic pro-
ﬁles, we investigated whether TF regulators could be
identiﬁed with an upstream role unique to aHCFs or
fHCFs. A de novo motif analysis was performed with
Homer on H3K4me3 loci (taken to represent active
gene promoters) associated with differentially
expressed genes in aHCFs and fHCFs. Two motifs and
their corresponding TFs were enriched in differential
H3K4me3 loci of each cell type (Figure 4A). Notably,
the 2 TFs identiﬁed in fHCFs (SOX17 and SOX4) and
the 2 for aHCFs (PLAGL1 and STAT1) were also
strongly differentially up-regulated in their corre-
sponding cells on the basis of their corresponding
RNA-seq data. We accurately replicated these ﬁnd-
ings further in 3 (2 adult and 1 fetal) additional
independent HCF cell isolates (Supplemental
Figure 6A). These TFs now represent novel regula-
tors that may play an important role in their respec-
tive cells.
TF VALIDATION BY GapmeR KNOCKDOWN. The
therapeutic potential of targeting aHCFs in adult car-
diac disease led us to choose PLAGL1 and STAT1 for
validation by in vitro knockdown using GapmeR oli-
gonucleotides. We performed this procedure in all 3
aHCF lines (Table 1). PLAGL1 and STAT1 knockdown
led to >80% reduced expression levels when targeted
with GapmeRs (Figure 4B, Supplemental Figure 6B).
Interestingly, PLAGL1 knockdown also led to reduced
FIGURE 4 TF Identiﬁcation and Validation
(A) Transcription factor (TF) motifs enriched at active promoters (marked by H3K4me3) of differentially expressed genes for each aHCF and fHCF. Expression of each
corresponding TF gene taken from RNA-seq data is also shown. (B) Effective >90% GapmeR-mediated knockdown (k.d.) of PLAGL1 and STAT1 in aHCFs shown by reverse
transcription quantitative–polymerase chain reaction, normalized to GAPDH and PPIA housekeeping gene control and subsequently to negative A (NegA) control. Values
are mean  SD. (C) Knockdown of either PLAGL1 or STAT1 leads to changes in the aHCF phenotype compared with control specimens. (D) Quantiﬁcation of cellular
parameters after knockdown of either TF shows that aHCFs become smaller and rounder after STAT1 knockdown. PLAGL1 knockdown also results in increased
proliferation. All experiments were conducted as n ¼ 3. Biological repeats in independent human cardiac ﬁbroblast cell isolates are shown in Supplemental Figure 6.
Values are mean  SD. *p < 0.05 compared with NegA control. Abbreviations as shown in Figures 1 and 3.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 7 , 2 0 1 6 Jonsson et al.
D E C E M B E R 2 0 1 6 : 5 9 0 – 6 0 2 Human Adult and Fetal Cardiac Fibroblast Epigenomes
597STAT1 levels, suggesting an upstream effect of
PLAGL1 on STAT1 that has not been previously re-
ported. Negative A GapmeR construct, vehicle trans-
fection, and nontransfected control specimens were
used in all assessments. Cells were stained with anti-
bodies against vimentin and Ki67 and analyzed for cell
size, roundness, cell cycle, and cell number (n ¼ 3).
Cell size, morphology, or cell number was un-
changed in all control specimens (Figures 4C and 4D).
Instead, knockdown of STAT1 signiﬁcantly increased
cell roundness, reduced cell number without in-
creasing cell proliferation, and knockdown of either
TF changed aHCF cell size (Figure 4D, replicated in
independent cell isolates in Supplemental Figure 6C).
Changes at the transcriptional level revealed that
whereas VIM and SMA were unchanged, both STAT1and PLAGL1 knockdown caused signiﬁcant down-
regulation of other genes previously noted as being
characteristic of the aHCF phenotype (ELN,
TNFRSF11B, COL1A1, and COL1A2). Conversely,
HBEGF associated with the fetal gene proﬁle was up-
regulated (Figure 5A, also replicated in independent
cell isolates in Supplemental Figure 6D).
To test whether knockdown ﬁbroblasts underwent
mesenchymal epithelial transition (21), key markers
for epithelial cells (CDH1, KRT9, and ATP2C2) were
quantiﬁed, but these remained poorly expressed or
undetected, rejecting the possibility that this transi-
tion had taken place (Supplemental Figure 6D). We
next assessed for apoptosis by using the ApopTag-
Red assay. Baseline apoptosis of aHCFs in culture
was 3% (untreated cells, n ¼ 5,237), 5% (cells treated
FIGURE 5 STAT1 Knockdown Induces Fibroblast Senescence and Reduced Collagen Gene Expression
Continued on the next page
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599with control vehicle lipofectamine alone, n ¼ 4,992),
and 6% (cells treated with control negative A
GapmeR, n ¼ 3,710). In contrast, knockdown of
PLAGL1 or STAT1 led to signiﬁcant up-regulation
of apoptosis to 29% in PLAGL1 knockdown cells
(n ¼ 2,500) and 156% in STAT1 knockdown cells
(n ¼ 2,739; >100% apparent apoptosis is due to
automated detection of multiple ApopTag-Red–
stained granules in many cells) (Figure 5B).
Interestingly, apart from the classical ApopTag-
Red–positive staining of nuclei to mark apoptotic
cells, an overwhelming number of STAT1 knockdown
cells were also noted that showed cytoplasmic frag-
mentation labeling. This ﬁnding was replicated more
than 3 times and was absent both in PLAGL1 knock-
down cells and in DNase1-treated positive control
cells. At this time, we considered the possibility that
cytoplasmic labeling represents advanced apoptosis
in STAT1 knockdown cells or evidence of widespread
mitochondrial damage.
Furthermore, a signiﬁcant up-regulation of the
classical marker for ﬁbroblast senescence MMP3
(1,400-fold compared with control), as well as a subtle
up-regulation of RB1 and TP53 (also markers of cell
senescence), were noted in STAT1 knockdown aHCFs
(Figure 5A). Signiﬁcant up-regulation of MMP3 was
replicated in 1 of 2 of the additional aHCF cell
isolates. The third cell line instead showed a signiﬁ-
cant up-regulation of RB1 (Supplemental Figure 6D).
High-power magniﬁcation of 40,6-diamidino-2-
phenylindole–stained nuclei showed formation of
heterochromatin foci in 9% of STAT1 knockdown
aHCFs (n ¼ 5,595), whereas this outcome was not seen
in untreated or positive control cells and in <1%
after PLAGL1 knockdown (n ¼ 4,899). Cells with
heterochromatin foci were frequently positive for
ApopTag-Red (Figure 5C), although not all ApopTag-
Red–positive cells showed heterochromatin foci.
Instead, we observed a striking exclusivity in which
nuclei displaying the heterochromatin foci were
never positive for Ki67 (Figure 5D). Together, theseFIGURE 5 Continued
(A) Reverse transcription quantitative–polymerase chain reaction of repr
ﬁbroblast genes VIM and SMA are unchanged, genes associated with the
is up-regulated. Apoptosis-related genes such as BAX, CASP3, PCNA, an
marker MMP3, as well as RB1 and TP53 showed strong upregulation fol
knockdown of both TFs. Values are mean  SD and taken from at least
shown in Supplemental Figure 6. (B) Apoptosis was assessed by using t
apoptosis under control conditions (control Neg. A GapmeR transfection)
after PLAGL1 and STAT1 knockdown. A strikingly high level of cytoplasm
others. (C) Heterochromatin foci were detected in 9% (450 of 5,595 nuc
with the ApopTag-Red stain. (D) Nuclei illustrating that heterochromatiﬁndings suggest that whereas 1 subset of knockdown
aHCFs undergoes apoptosis, another appears to
become senescent. Furthermore, STAT1 and PLAGL1
knockdown led to a signiﬁcant reduction in collagen
COL1A1 and COL1A2 gene expression (Figure 5A).
These results were again supported by RT-qPCR in all
additional sets of aHCF cells.
DISCUSSION
Results of previous studies indicated that fHCFs and
aHCFs are different in that they inﬂuence neighboring
CMs in distinct ways (6,13). In the present study, we
have further deﬁned their distinct differences by
performing a thorough characterization of primary
fetal and adult human ventricular CFs by using
cellular, molecular, and genome-wide sequencing
approaches. Our results show that fHCFs are smaller
and proliferate more quickly than their adult coun-
terpart. We hypothesized that these characteristics
are explained by differences in their transcriptomes
and epigenomes. Indeed, genome-wide analyses of
RNA-seq, ATAC-seq, and histone ChIP-seq led us to 2
TFs, highly expressed in aHCFs but not in fHCFs. We
performed functional validation to conclude that they
regulate aHCF cell size, cell cycle re-entry, and cell
survival. Knockdown of either of the 2 TFs led to a
destabilization of the aHCF phenotype and reduced
gene expression of collagen genes, a major constituent
of pathological ﬁbrosis in the adult heart.
RNA-seq CONFIRMS FIBROBLAST IDENTITY AND
IDENTIFIES DIFFERENTIAL SIGNALING PATHWAYS.
We ﬁrst conﬁrmed that “core” genes that deﬁne a
ﬁbroblast and that are typically used as ﬁbroblast
markers, such as VIM, THY1, DDR2, and COL1A2, do
not differ in expression between fHCFs and aHCFs.
According to IPA analysis, 3 top functions found in
the overlapping transcriptomes of the fHCFs and
aHCFs are tissue development, cardiovascular
system development and function, and organismal
development, validating our cardiac cell source andesentative genes after PLAGL1 or STAT1 knockdown in aHCFs. Whereas common human cardiac
adult phenotype are down-regulated (ELN and TNFRSF11B), and HBEGF (associated with fHCFs)
d MCM3 are in particular up-regulated after STAT1 knockdown. Similarly, cellular senescence
lowing STAT1 knockdown. Collagen genes (COL1A1 and COL1A2) are down-regulated upon
n ¼ 3. All p < 0.05, Student t test. Biological repeats from independent aHCF cell isolates are
he ApopTag-Red assay that detects DNA fragmentation. A low number of cells (6%) exhibited
, and this was signiﬁcantly up-regulated in the positive control (DNAse I–treated cells) as well as
ic ApopTag-labeling was repeatedly evident in STAT1 knockdown cells, which was not seen in
lei analyzed) of STAT1 knockdown cells. These foci frequently, but not exclusively, overlapped
n foci were never found in Ki67-positive cells. Abbreviations as in Figures 1, 3, and 4.
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600supporting the conclusion that fHCF and aHCF tran-
scriptomes do not differ substantially. Conversely,
this ﬁnding implied that important differences would
be decidedly more subtle. Nonoverlapping gene
functions are embryonic development and organ-
ismal survival for fHCFs, reﬂecting their fetal origin
(22,23), and immune cell trafﬁcking and skeletal and
muscular system development and function for
aHCFs, suggesting how aHCFs may have a different
role in the adult human heart compared with their
fetal counterpart. We used 2 additional HCF lines to
validate the RNA-seq to show that differential gene
expression was conﬁrmed across independent bio-
logical replicates. Among these are likely to be bona
ﬁde markers that can be used to distinguish between
aHCFs and fHCFs.
NOVEL AND INTERESTING GENES IDENTIFIED. Dif-
ferences in transcriptomes between cell types may
help us to understand and explain their differential
functions. For example, we expected that the fHCF
transcriptome would contain genes that reveal their
role for the developing heart and for inducing
appropriate heart growth, whereas the aHCF tran-
scriptome should comprise genes involved in the
maintenance of a heart that is already matured.
We therefore dissected the gene pathways and
functions speciﬁc to each differentially expressed
transcriptome for this analysis. Genes of the ephrin-
receptor and ephrin b–signaling pathways were
enriched in fHCFs. Indeed, ephrin B2 is important in
the developing heart for ventricular chamber
morphogenesis (24). Coherent to this process is the
importance of Notch signaling; we also found that the
Notch pathway is present in fHCFs but not aHCFs.
Ephrin signaling has further been implicated for the
development of vasculature (25). The ﬁnding of IL-8
signaling and ephrin signaling in fHCFs therefore
suggests a role for fHCFs in vascular development as
well. VCAM-1 is among the highest differentially
expressed genes in fHCFs, and VCAM-1 has known
importance for cardiac development because Vcam1
null mice embryos do not survive past E13.5 due to
retarded heart growth (23). Interestingly, ITGA4 is
also among the highest differentially expressed genes
in fHCFs, and ITGA4 is an endogenous ligand for
VCAM-1, creating the opportunity for inter-fHCF
communication that might guide cardiac develop-
ment. We also noted that analysis of gene ontology
cellular processes revealed more profound plasma
membrane components in fHCFs, such as integrins
and other receptors, whereas aHCF-speciﬁc genes
seem to focus on extracellular components. HBEGF is
yet another gene that is highly expressed in fHCFsand lacking in aHCFs. HBEGF has been reported to
promote cardiomyocyte proliferation in a paracrine
fashion in a mouse model (6), and our data support its
importance exclusively in fHCFs.
Among the top differentially expressed genes in
aHCFs is FGF7. A gene network of FGF signaling in IPA
also showed that 10 of the 15 genes involved in FGF
signaling were highly differentially expressed in
aHCFs, with other members of the network, including
FGF2 and FGF14. Although it is well established that
the FGF superfamily of growth factors is important in
pathophysiological processes within the cardiac
environment (26), a speciﬁc role for FGF7 has yet to be
deﬁned. Another gene more highly expressed in
aHCFs was TNFRSF11B encoding for osteoprotegerin,
a mesenchymal marker for EMT, from which a large
population of adult CFs is proposed to derive (27).
Overexpression of TNFRSF11B in rat CFs increased the
expression of ﬁbrosis-related proteins after treatment
with angiotensin II, whereas its knockdown produced
the reverse effect (28). ELN (elastin) is a third gene
highly expressed in aHCFs. Elastin is a major contrib-
utor to the ECM, and it functions together with ﬁbrillin
to provide elasticity to a range of tissues (29). Inter-
estingly, overexpression of ELN in cells that were
transplanted to infarcted cardiac tissue in rats
ameliorated the formation of scar tissue, compared
with infarcted cardiac tissue that received vector-
transduced cells (30). A necessity for crosslinking of
elastin ﬁbers is the presence of lysyl oxidases (29), and
LOXL4 (lysyl oxidase–like 4) is also one of the highest
differentially expressed genes in aHCFs.
PUTATIVE REGULATORY TFs FOR FETAL HCFs
DETERMINED BY USING MOTIF ANALYSIS. TFs
determined by using de novo motif analysis add
another layer of information to the regulation of the
differential transcriptomes between aHCFs and
fHCFs. We performed motif analysis by using active
promoters, demarcated according to H3K4me3, of
differentially expressed genes for either aHCFs or
fHCFs, thus specifying TFs for the respective tran-
scriptomes. Top motifs were SOX17 and SOX4 in
fHCFs. Importantly, these TFs were also all highly
expressed genes in fHCFs compared with aHCFs.
SOX17 is also expressed in endothelial cells, where
it regulates angiogenesis under the inﬂuence of Notch
signaling (31). Our results show that SOX17 is
expressed in fHCFs as well. SOX4 is a master regu-
lator of EMT and is needed for proper formation of the
cardiac outﬂow tract (32,33). Together, the abundant
expression of these 2 TFs in fHCFs suggests that they
may maintain prefate determination functions,
and/or that fHCFs have a role in the development of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: We report
important genome-wide differences between fHCFs and aHCFs
and identiﬁed key players responsible for maintaining the adult
HCF phenotype. Our data suggest that this source of HCFs is
useful in translational research, such as for disease modeling
of cardiac ﬁbrosis.
TRANSLATIONAL OUTLOOK: The transcription factors
identiﬁed (PLAGL1 and STAT1) may be potential drug targets for
steering away the malevolent behavior of HCFs during progres-
sion of adult heart disease.
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601the vasculature of the heart, similar to the ephrin and
IL-8 signaling discussed earlier.
REGULATORY TFs IN aHCFs FOUND BY MOTIF
ANALYSIS AND VALIDATED IN VITRO. The top 2 TFs
identiﬁed for aHCFs were PLAGL1 and STAT1, and
their corresponding messenger ribonucleic acid was
indeed signiﬁcantly highly expressed in aHCFs
compared with fHCFs. PLAGL1 is an important TF in
the developing heart, but its role has only been linked
to CMs rather than CFs (34). In our experiments,
knockdown of PLAGL1 in aHCFs led to reduced cell
size and increased apoptosis. STAT1 activation
reportedly increases ﬁbroblast activation and
collagen synthesis induced by high glucose levels
(35). In our experiments, STAT1 knockdown in aHCFs
also led to reduced cell size and apoptosis. Gene
expression analysis after knockdown showed that
VIM and SMA levels remained unchanged, indicating
that STAT1 knockdown cells were not transforming to
myoﬁbroblasts. Instead, markers associated with the
adult phenotype were down-regulated, and fetal
markers were up-regulated. Together with their
smaller size and increased apoptosis, we interpret
these changes to represent a de-stabilization of the
aHCF phenotype and viability.
We also found evidence for cell senescence based
on the very high up-regulation of the classical ﬁbro-
blast senescence marker MMP3 and concomitant up-
regulation of other senescence markers (RB1 and
TP53) (36,37). Consistent with this ﬁnding was the
formation of heterochromatin foci in knockdown
cells. Cells with heterochromatin foci were mutually
exclusive from Ki67-positive cells, consistent with
the description of senescence-associated hetero-
chromatin foci that have already been extensively
described (38). Concurrently, the expression of
collagen genes COL1A1 and COL1A2 as well as
TNFRSF11B were strongly down-regulated, suggest-
ing that STAT1 knockdown cells have a diminished
ability to stimulate proﬁbrotic processes. Impor-
tantly, these ﬁndings were conﬁrmed in independent
sets of aHCF cells from different donors.
CONCLUSIONS
Overall, this report describes for the ﬁrst time
important genome-wide differences between fHCFsand aHCFs. Signals from loci of active promoters led
to the identiﬁcation of important TFs responsible for
the differential roles of HCFs. Although the exclusive
use of human material limited this research to in vitro
studies, these ﬁndings nevertheless reveal interesting
new explanations for the different ways in which ﬁ-
broblasts act in the human adult and fetal heart. Our
data further suggest that this source of HCFs may be
useful for translational research, such as for disease
modeling of cardiac ﬁbrosis, or for other uses, such as
improving CM maturation in differentiation protocols
from human embryonic stem cells. Our knockdown
studies for PLAGL1 and STAT1 suggest their impor-
tance for aHCF viability and phenotype maintenance.
Further in vivo studies will be needed to determine
whether they do indeed represent potential drug tar-
gets for steering away the malevolent behavior of CFs
during adult heart disease progression.
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